Diagnosis and treatment of impulse control disorders in patients with movement disorders

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 3, 2013, Pages 175-188

  Mestre, Tiago A ^a   Strafella, Antonio P ^a   Thomsen, Teri ^b   Voon, Valerie ^c   Miyasaki, Janis ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

dopamine agonist; Impulse control disorders; neurobehavioural; non motor complication; Parkinson's disease; parkinsonism; restless leg syndrome

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; AMANTADINE; CLOMIPRAMINE; CLOZAPINE; CYPROTERONE; DONEPEZIL; FINASTERIDE; LEVODOPA; LITHIUM; MEMANTINE; NALMEFENE; NALTREXONE; NICOTINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; HUMAN; IMPULSE CONTROL DISORDER; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PATIENT COUNSELING; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; SCREENING TEST; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL SUPPORT; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84879306848     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613476127     Document Type: Review

References (101)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association.
2. Ardouin C. Chereau I. Llorca P. Lhommee E. Durif F. Pollak P. et al (2009) [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease]. Rev Neurol (Paris) 165: 845–856.
3. Ardouin C. Voon V. Worbe Y. Abouazar N. Czernecki V. Hosseini H. et al (2006) Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21: 1941–1946.
4. Armon C. Shin C. Miller P. Carwile S. Brown E. Edinger J. et al (1996) Reversible Parkinsonism and cognitive impairment with chronic valproate use. Neurology 47: 626–635.
5. Avanzi M. Baratti M. Cabrini S. Uber E. Brighetti G. Bonfa F. (2008) The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome? Parkinsonism Relat Disord 14: 257–258.
6. Avila A. Cardona X. Martin-Baranera M. Bello J. Sastre F. (2011) Impulsive and compulsive behaviors in Parkinson's disease: a one-year follow-up study. J Neurol Sci 310: 197–201.
7. Bayard S. Yu H. Langenier M. Carlander B. Dauvilliers Y. (2010) Decision making in restless legs syndrome. Mov Disord 25: 2634–2640.
8. Bermejo P. (2008) Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 14: 448–449.
9. Bermejo P. Ruiz-Huete C. Anciones B. (2010) Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 257: 1682–1685.
10. Bienfait K. Menza M. Mark M. Dobkin R. (2010) Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. J Clin Neurosci 17: 539–540.
11. Bortolato M. Cannas A. Solla P. Bini V. Puligheddu M. Marrosu F. (2012) Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol 32: 424–425.
12. Bosco D. Plastino M. Colica C. Bosco F. Arianna S. Vecchio A. et al (2012) Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 35: 118–120.
13. Christenson G. Faber R. de Zwaan M. Raymond N. Specker S. Ekern M. et al (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55: 5–11.
14. Cilia R. Ko J. Cho S. van Eimeren T. Marotta G. Pellecchia G. et al (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 39: 98–104.
15. Cooper C. Jadidian A. Paggi M. Romrell J. Okun M. Rodriguez R. et al (2009) Prevalence of hypersexual behavior in Parkinson's disease patients: not restricted to males and dopamine agonist use. Int J Gen Med 2: 57–61.
16. Cornelius J. Tippmann-Peikert M. Slocumb N. Frerichs C. Silber M. (2010) Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33: 81–87.
17. Evans A. Butzkueven H. (2007) Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 22: 590–591.
18. Evans A. Katzenschlager R. Paviour D. O'Sullivan J. Appel S. Lawrence A. et al (2004) Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19: 397–405.
19. Evans A. Lawrence A. Potts J. Appel S. Lees A. (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65: 1570–1574.
20. Evans A. Stegeman J. (2009) Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord 24: 140–141.
21. Fasano A. Elia A. Soleti F. Guidubaldi A. Bentivoglio A. (2006) Punding and computer addiction in Parkinson's disease. Mov Disord 21: 1217–1218.
22. Fasano A. Ricciardi L. Pettorruso M. Bentivoglio A. (2011) Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 258: 656–660.
23. Fernandez H. Durso R. (1998) Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 13: 597–598.
24. Fernandez H. Friedman J. (1999) Punding on L-dopa. Mov Disord 14: 836–838.
25. Fernandez H. Trieschmann M. Burke M. Jacques C. Friedman J. (2003) Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18: 510–514.
26. Ferrara J. Stacy M. (2008) Impulse-control disorders in Parkinson's disease. CNS Spectr 13: 690–698.
27. Ferris J. Stripe T. Ialomiteanu A. (1996) Gambling in Ontario: A Report from a General Population Survey on Gambling-Related Problems and Opinions. ARF Document Series no. 130. Toronto: Addiction Research Foundation, December 1996.
28. Friedman J. (1994) Punding on levodopa. Biol Psychiatry 36: 350–351.
29. Fulda S. Beitinger M. Reppermund S. Winkelmann J. Wetter T. (2010) Short-term attention and verbal fluency is decreased in restless legs syndrome patients Mov Disord 25: 2641–2648.
30. Fulda S. Szesny N. Ising M. Heck A. Grübl A. Lieb R. et al (2011) Further evidence for executive dysfunction in subjects with RLS from a non-clinical sample. Sleep Med 12 (10): 1003–1007.
31. Gallagher D. O'Sullivan S. Evans A. Lees A. Schrag A. (2007) Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22: 1757–1763.
32. Galpern W. Stacy M. (2007) Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol 9: 189–197.
33. Giovannoni G. O'Sullivan J. Turner K. Manson A. Lees A. (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68: 423–428.
34. Grant J. Odlaug B. Potenza M. Hollander E. Kim S. (2010) Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 197: 330–331.
35. Grosset D. Cardoso F. Lees A. (2011) Dopamine agonists vs levodopa in impulse control disorders. Arch Neurol 68: 544–545; author reply 545–546.
36. Gschwandtner U. Aston J. Renaud S. Fuhr P. (2001) Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24: 170–172.
37. Hicks C. Pandya M. Itin I. Fernandez H. (2011) Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 17: 379–381.
38. Isaias I. Siri C. Cilia R. de Gaspari D. Pezzoli G. Antonini A. (2008) The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 23: 411–415.
39. Ivanco L. Bohnen N. (2005) Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther 12: 467–468.
40. Jimenez-Jimenez F. Sayed Y. Garcia-Soldevilla M. Barcenilla B. (2002) Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36: 1178–1179.
41. Kafka M. (2010) Hypersexual disorder: a proposed diagnosis for DSM-V. Arch Sex Behav 39: 377–400.
42. Kashihara K. Imamura T. (2008) Amantadine may reverse punding in Parkinson's disease–observation in a patient. Mov Disord 23: 129–130.
43. Kim S. Grant J. Potenza M. Blanco C. Hollander E. (2009) The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res 166: 76–84.
44. Kim Y. Park H. Kim J. Kim K. (2008) Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 20: 496–497.
45. Klos K. Bower J. Josephs K. Matsumoto J. Ahlskog J. (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11: 381–386.
46. Koran L. Faber R. Aboujaoude E. Large M. Serpe R. (2006) Estimated prevalence of compulsive buying behavior in the United States. Am J Psychiatry 163: 1806–1812.
47. Kurlan R. (2004) Disabling repetitive behaviors in Parkinson's disease. Mov Disord 19: 433–437.
48. Lesieur H. Blume S. (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144: 1184–1188.
49. Leu-Semenescu S. Karroum E. Brion A. Konofal E. Arnulf I. (2009) Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Med 10: 494–496.
50. Lim S. Evans A. Miyasaki J. (2008) Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 1142: 85–107.
51. Lim S. O'Sullivan S. Kotschet K. Gallagher D. Lacey C. Lawrence A. et al (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 16: 1148–1152.
52. Macphee G. Copeland C. Stewart D. Grosset K. Grosset D. (2009) Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord 24: 2430–2431.
53. Mamikonyan E. Siderowf A. Duda J. Potenza M. Horn S. Stern M. et al (2008) Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23: 75–80.
54. McElroy S. Guerdjikova A. Winstanley E. O'Melia A. Mori N. McCoy J. et al (2011) Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 44: 81–90.
55. McElroy S. Keck P. Jr Pope H. Jr Smith J. Strakowski S. (1994) Compulsive buying: a report of 20 cases. J Clin Psychiatry 55: 242–248.
56. McKeon A. Josephs K. Klos K. Hecksel K. Bower J. Michael Bostwick J. et al (2007) Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 13: 516–519.
57. Miwa H. Morita S. Nakanishi I. Kondo T. (2004) Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 10: 177–180.
58. Miyasaki J. Al Hassan K. Lang A. Voon V. (2007) Punding prevalence in Parkinson's disease. Mov Disord 22: 1179–1181.
59. Moum S. Price C. Limotai N. Oyama G. Ward H. Jacobson C. et al (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PloS ONE 7: e29768.
60. Nirenberg M. Waters C. (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21: 524–529.
61. O'Sullivan S. Djamshidian A. Ahmed Z. Evans A. Lawrence A. Holton J. et al (2010 a) Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord 25: 638–642.
62. O'Sullivan S. Djamshidian A. Evans A. Loane C. Lees A. Lawrence A. (2010 b) Excessive hoarding in Parkinson's disease. Mov Disord 25: 1026–1033.
63. O'Sullivan S. Evans A. Quinn N. Lawrence A. Lees A. (2010 c) Reckless generosity in Parkinson's disease. Mov Disord 25: 221–223.
64. Pallanti S. de Caria C. Grant J. Urpe M. Hollander E. (2005) Reliability and validity of the pathological gambling adaptation of the Yale–Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud 21: 431–443.
65. Papay K. Mamikonyan E. Siderowf A. Duda J. Lyons K. Pahwa R. et al (2011) Patient versus informant reporting of ICDsymptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17: 153–155.
66. Perez-Lloret S. Rey M. Fabre N. Ory F. Spampinato U. Brefel-Courbon C. et al (2012) Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 35: 261–265.
67. Petry N. Roll J. (2001) A behavioral approach to understanding and treating pathological gambling. Semin Clin Neuropsychiatry 6: 177–183.
68. Petry N. Stinson F. Grant B. (2005) Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66: 564–574.
69. Pezzella F. Colosimo C. Vanacore N. Di Rezze S. Chianese M. Fabbrini G. et al (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20: 77–81.
70. Pondal M. Marras C. Miyasaki J. Moro E. Armstrong M. Strafella A. et al (2011) Clinical features of dopamine agonist withdrawal syndrome (DAWS) in a movement disorders clinic. Movement Disorders 26: S110–S111.
71. Pontone G. Williams J. Bassett S. Marsh L. (2006) Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67: 1258–1261.
72. Quickfall J. Suchowersky O. (2007) Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 13: 535–536.
73. Quinn N. Toone B. Lang A. Marsden C. Parkes J. (1983) Dopa dose-dependent sexual deviation. Br J Psychiatry 142: 296–298.
74. Rabinak C. Nirenberg M. (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67: 58–63.
75. Rodriguez-Oroz M. Obeso J. Lang A. Houeto J. Pollak P. Rehncrona S. et al (2005) Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128: 2240–2249.
76. Rylander G. (1972) Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 75: 203–212.
77. Schreglmann S. Gantenbein A. Eisele G. Baumann C. (2012) Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord 18: 207–209.
78. Seppi K. Weintraub D. Coelho M. Perez-Lloret S. Fox S. Katzenschlager R. et al (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26(Suppl. 3): S42–S80.
79. Sevincok L. Akoglu A. Akyol A. (2007) Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 27: 107–108.
80. Shaffer H. LaBrie R. Scanlan K. Cummings T. (1994) Pathological gambling among adolescents: Massachusetts Gambling Screen (MAGS). J Gambl Stud 10: 339–362.
81. Shapiro M. Chang Y. Munson S. Okun M. Fernandez H. (2006) Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 12: 392–395.
82. Silveira-Moriyama L. Evans A. Katzenschlager R. Lees A. (2006) Punding and dyskinesias. Mov Disord 21: 2214–2217.
83. Singh A. Kandimala G. Dewey R. Jr. O'Suilleabhain P. (2007) Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 14: 1178–1181.
84. Smeding H. Goudriaan A. Foncke E. Schuurman P. Speelman J. Schmand B. (2007) Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 78: 517–519.
85. Solla P. Cannas A. Floris G. Orofino G. Costantino E. Boi A. et al (2011) Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry 35: 1009–1013.
86. Steeves T. Miyasaki J. Zurowski M. Lang A.E. Pellecchia G. van Eimeren T. et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132: 1376–1385.
87. Thomas A. Bonanni L. Gambi F. Di Iorio A. Onofrj M. (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68: 400–404.
88. Tomlinson C. Stowe R. Patel S. Rick C. Gray R. Clarke C. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25 (15): 2649–2653.
89. Uitti R. Tanner C. Rajput A. Goetz C. Klawans H. Thiessen B. (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12: 375–383.
90. van Eimeren T. Pellecchia G. Cilia R. Ballanger B. Steeves T. Houle S. et al (2010) Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 75: 1711–1716.
91. Volkmann J. Allert N. Voges J. Sturm V. Schnitzler A. Freund H. (2004) Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 55: 871–875.
92. Voon V. Hassan K. Zurowski M. de Souza M. Thomsen T. Fox S. et al (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67: 1254–1257.
93. Voon V. Schoerling A. Wenzel S. Ekanayake V. Reiff J. Trenkwalder C. et al (2011 a) Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 11: 117.
94. Voon V. Sohr M. Lang A. Potenza M. Siderowf A. Whetteckey J. et al (2011 b) Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol 69: 986–996.
95. Voon V. Thomsen T. Miyasaki J. de Souza M. Shafro A. Fox S. et al (2007) Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64: 212–216.
96. Weintraub D. Hoops S. Shea J. Lyons K. Pahwa R. Driver-Dunckley E. et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 24: 1461–1467.
97. Weintraub D. Koester J. Potenza M. Siderowf A. Stacy M. Voon V. et al (2010 a) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67: 589–595.
98. Weintraub D. Mamikonyan E. Papay K. Shea J. Xie S. Siderowf A. (2012) Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord 27: 242–247.
99. Weintraub D. Siderowf A. Potenza M. Goveas J. Morales K. Duda J. et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63: 969–973.
100. Weintraub D. Sohr M. Potenza M. Siderowf A. Stacy M. Voon V. et al (2010 b) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68: 963–968.
101. Zahodne L. Susatia F. Bowers D. Ong T. Jacobson C. Okun M. et al (2011) Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci 23: 56–62.